OTC Watch

All stocks / VXRT

Vaxart, Inc. VXRT

Vaxart (VXRT): financing deals mentioned in an 8-K in April 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatCostly financing OTCQXCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
VAXART INC
Market tier
OTCQX US
Trading status
Active
Last trade
09:57:11
Website
www.vaxart.com
Source: Stockwatch, 2026-11-17

News headlines

Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-05 16:05 · News Release
Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET
2026-10-29 08:00 · News Release
Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
2026-10-19 08:00 · News Release
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
2026-10-08 08:41 · News Release
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 08:00 · News Release
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
2026-08-26 16:08 · News Release
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-06 16:05 · News Release
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
2026-07-30 08:00 · News Release
Vaxart to Participate in BTIG Biotechnology Conference 2026
2026-07-21 08:00 · News Release
Vaxart Announces Results of Annual Meeting of Stockholders
2026-07-17 16:05 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$237,258,000
Net income
$16,327,000
What it means

It earned more than it spent

Steady

After all costs, the company kept $16.3 million as profit in the year.

The report says
Cash and cash equivalents
$53,814,000
Net cash from operating activities
$7,714,000
What it means

The business brings in cash

Steady

Day-to-day business added $7.7 million in cash over the year. It had $53.8 million in the bank.

The report says
Total assets
$186,079,000
Total liabilities
$98,281,000
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $186.1 million. Its debts and unpaid bills add up to $98.3 million. That is about $0.53 owed for every $1 owned.

What this adds up to

0 of 3 checks show strain. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-10-30

Estimated float about 237,302,740 shares as of 2026-10-30: 243,702,034 outstanding minus 6,399,294 held by 11 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-04-17

8-K filed 2026-04-17 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-12-31
240.5M
2026-03-06
240.6M
2026-03-31
241.4M
2026-05-01
242.0M
2026-06-30
242.8M
2026-07-31
242.8M
2026-09-30
243.7M
2026-10-30
243.7M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-05 8-KFORM 8-K
2026-11-05 10-QFORM 10-Q
2026-10-20 3FORM 3
2026-10-20 4FORM 4
2026-10-19 8-KFORM 8-K
2026-09-14 8-KFORM 8-K
2026-08-25 8-KFORM 8-K
2026-08-06 8-KFORM 8-K
2026-08-06 10-QFORM 10-Q
2026-07-28 8-KFORM 8-K
2026-07-20 4FORM 4
2026-07-17 8-KFORM 8-K

Common questions about VXRT

Does VXRT file reports with the SEC?

Yes. Vaxart files with the SEC under company number 0000072444. The most recent filing we hold is a 8-K dated 2026-11-05.

Source record

How many VXRT shares are outstanding?

243,702,034 shares as of 2026-10-30, as reported to the SEC.

Source record

Has VXRT filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Vaxart?

Officers named in its insider filings: Edward B Berg (SVP, General Counsel), James F. Cummings (Chief Medical Officer) and Jeroen Nicolaas Grasman (Chief Financial Officer).

Source record

Is Vaxart making money?

After all costs, the company kept $16.3 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record